Article Text

other Versions

PDF
APOE ε4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan
  1. Pei-Ning Wang1,2,
  2. Chen-Jee Hong3,4,
  3. Ker-Neng Lin2,5,
  4. Hsiu-Chih Liu1,2,
  5. Wei-Ta Chen1,2
  1. 1Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan
  2. 2Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan
  3. 3Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
  4. 4Department of Psychiatry, National Yang-Ming University School of Medicine, Taipei, Taiwan
  5. 5Department of Psychology, Fu Jen Catholic University, Taipei County, Taiwan
  1. Correspondence to Dr Pei-Ning Wang, Department of Neurology, Taipei Veterans General Hospital, Taipei, 112, Taiwan; pnwang{at}vghtpe.gov.tw

Abstract

Objective To evaluate the effect of the apolipoprotein E (APOE) ε4 in the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) in ethnic Chinese people in Taiwan.

Methods Subjects older than 60 years with normal cognition, MCI or AD were enrolled from the memory clinic from 2000 to 2008. Normal ageing and MCI subjects were evaluated with clinical and neuropsychological examinations annually, and their APOE genotypes were determined.

Results A total of 326 normal ageing subjects, 304 amnestic MCI and 537 AD patients were recruited at baseline. The frequencies of APOE ε4 were 22.1% in normal ageing, 26.6% in MCI and 40.8% in AD patients. During the follow-up period (42.5±18.5 months), there were 227 MCI patients, and 248 normal ageing subjects received one or more annual follow-up evaluation. The ε4+carriers had a higher annual conversion rate than did the ε4-negative subjects either in the MCI (15.9% vs 9.0%) or in the normal ageing subjects (2.2% vs 0.7%). The mean survival time before progression to AD was 57.0 months for the MCI ε4+carriers, 85.9 months for MCI ε4-negative patients, 86.2 months for normal ageing e4+carriers and 120.8 months for normal ageing ε4-negative subjects. The adjusted hazard ratio of APOE ε4 for developing AD was 2.0 (95% CI 1.2 to 3.2) in MCI and 5.3 (95% CI 1.2 to 24.1) in normal ageing.

Conclusion APOE ε4 increased the risk of developing AD both in amnestic MCI and in normal ageing in a clinic-recruited ethnic Chinese population.

  • Apolipoprotein E
  • Alzheimer's disease
  • mild cognitive impairment
  • amnesia
  • cognition
  • dementia
  • neurogenetics

Statistics from Altmetric.com

Footnotes

  • Funding National Science Council (NSC 95-2314-B-075-002, NSC97-2314-B-010-011) and Taipei Veterans General Hospital (V95ER3-002).

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Institutional Review Board of the Taipei Veterans General Hospital, Taipei, Taiwan.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.